JCP Summarizes Baumgardner Study on CAR-T Treatment Cost-Effectiveness

In the latest edition of the Journal of Clinical Pathways (JCP), Zachary Bessette summarizes PHE Senior Research Economist Jim Baumgardner’s recent ASH presentation, focused on studying the cost-effectiveness of novel CAR-T treatments. In the study, Dr. Baumgardner’s team asserts that the introduction of CAR-T therapies represents a major break from the trend of declining incremental effectiveness and provides similar cost-effectiveness to other innovations.

To read the summary in JCP, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.